Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
Secondary cytoreduction followed by chemotherapy versus chemotherapy alone in platinum-sensitive relapsed ovarian cancer (SOC-1): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:1402011
Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial | Annals of Surgical Oncology
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Dr. STEFANY CARDOSO FARIA - MÉDICO ONCOLOGISTA: #ASCO 2017 Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III/ENGOT ov20
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial - The Lancet
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer | NEJM
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
![PDF] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/9f70a61bd62289d61bdc1f3b559d831e3bc47919/4-Figure1-1.png "PDF] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study | Semantic Scholar")
PDF] A phase II trial of cytoreductive surgery combined with niraparib maintenance in platinum-sensitive, secondary recurrent ovarian cancer: SGOG SOC-3 study | Semantic Scholar
Last improvements in advanced ovarian cancer treatment | Com&Co Group
New Data Support Debulking to Prolong Survival in Women With Platinum-Sensitive Recurrent Ovarian Cancer | ASCO Daily News
PDF) Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial
PPT - AGO-OVAR DESKTOP III (Protocol AGO - OVAR OP.4) PowerPoint Presentation - ID:3272978
Ovarian Committee. Closed Trials Upfront Surgery vs Neoadjuvant Chemotherapy Patients closed / 550 Leading EORTC Participating NCIC CTG Presentation. - ppt download
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
This #ASCO20 was notable for two major trials exploring secondary cytoreductive surgery in recurrent #ovariancancer - DESKTOP III and SOC -1 #ASCO20 # - Thread from Shannon Westin @ShannonWestin - Rattibha
Activities and medical courses available now | CCO
Table 4 from Surgical management of recurrent ovarian cancer. | Semantic Scholar
Saturday, May 30, :00 PM - 9:00 PM The Peabody Orlando Orlando, Florida Ovarian Cancer: Recent Developments in the Standard of Care and Emerging. - ppt download
Advances in ovarian cancer, from biology to treatment | Nature Cancer
PPT - An Oncology Exchange Activity PowerPoint Presentation, free download - ID:5600388
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer | NEJM
Cytoreductive surgery before chemotherapy benefits women with recurrent ovarian cancer
Clinical Conundrums: Choosing the Best Management Approaches in Patients With Ovarian Cancer Thomas J. Herzog, MD Director, Division of Gynecologic Oncology. - ppt download
